Learn more about the ongoing Tetra trials in 2 minutes with Dr. Liz Berry-Kravis

By Hilary Rosselot

Tetra Therapeutics, a Shionogi Group Company, is running trials on BPN14770 (zatolmilast) in adult and adolescent males with full mutation Fragile X syndrome.

In this two-minute video, Dr. Liz Berry-Kravis shares what participants are asked to do during the trial, who is eligible, and how to learn more.

learn more

Learn more and contact a site near you by visiting the MyFXResearch post and completing the contact form at the bottom of the post: https://fragilex.org/opportunities-for-families/tetra-bpn14770/

  • Children Are Our Commitment: Explore Our Fragile X Syndrome Clinical Trial Today

Clinical Trial RECONNECT: ZYN002 Gel

This study will evaluate the efficacy and safety of ZYN002, a clear gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X syndrome (FXS).

about
Author Hilary Rosselot

Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!